Dr. Subir Basak is an accomplished global financial and general management expert in biotechnology, pharma, health, and medtech and has been an entrepreneur since 2015. He has spent more than 20 years in roles of increasing responsibility from Merck Fellow, General Manager, and CEO/President. He has been the Whole-time Director to Jubilant, Intas and the Board Member of Aragen in the United States. He has also been the Managing Director of El-Lilly Joint Venture Vanthys. He is a TIE Charter Member and Investor in many companies in India and has successfully done dozens of transactions with B2B Clients. He is currently serving as a WHO taskforce member for the COVID-19 response and also on the Global Steering Committee for Pharma security involving several multilateral organizations.
Dr. Basak is part of the global life sciences team of IFC (World Bank Group) that oversees the $2 billion portfolio of the Health and Pharma practice. He has also worked with private equity and hedge funds prior to IFC and was a Kitven Fund IC member. Dr. Basak was the President at Jubilant Life Sciences, CEO at Intas BioPharma, and Global Specialties Head at Dr Reddys Laboratories. He has also worked for Amgen, Merck, and Bayer Pharmaceuticals.
Dr. Basak received an MS and PhD in Biochemical Engineering from Purdue University, an MBA from the Kellogg School of Management at Northwestern University, and BE in Chemical Engineering from the Indian Institute of Technology. He has done advanced management programs at the Harvard Business School and the Wharton School at the University of Pennsylvania.